Drug Profile
Gepotidacin - GSK
Alternative Names: GSK 2140944; GSK-2140944ELatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; INSERM
- Class Acenaphthenes; Antibacterials; Aza compounds; Ketones; Piperidines; Pyridines; Pyrones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gonorrhoea; Urinary tract infections
- Phase II Skin and soft tissue infections
- No development reported Bacterial infections; Respiratory tract infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Bacterial-infections in Austria (PO, Tablet)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Bacterial-infections in France (PO, Tablet)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Gonorrhoea in Austria (PO, Tablet)